PDE5 inhibitors, such as sildenafil, tadalafil and vardenafil have been widely used for treatment of PAH by increasing cGMP levels in vascular smooth muscle cells, leading to vascular smootmuscle relaxation, and thus vasodilation [73]. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.